Detailansicht

Wissensnetz

Person

Monika Engelhardt (1966-)

Ärztin

Name	Monika Engelhardt
Zeit	1966- (Lebensdaten)
Ort	Kiel (Geburtsort) Deutschland
Geschlecht	weiblich
Akademischer Grad bzw. Titel	Prof. Dr. med.
Beruf	Ärztin (charakteristischer Beruf) Hochschullehrerin
Variante	Monika Martha Engelhardt Monika M. Engelhardt M. Engelhardt
Beziehung	Universitätsklinikum Freiburg. Klinik für Innere Medizin I (2003-)
Weitere Angaben	Seit 1/2003 Oberärztin der Medizinischen Klinik, Abteilung Hämatologie und Onkologie; 2002 Habilitation Innere Medizin ; seit 7/2005 APL-Anerkennung Innere Medizin
Datensatztyp	Person
GND-Nummer	113263538
Datensatz-ID	113263538
Beteiligt an alle anzeigen Reduced intensity conditioning prior autologous stem cell transplantation in elderly DLBCL patients The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era Das interdisziplinäre Tumorboard „Multiples Myelom“ des Comprehensive Cancer Center Freiburg: eine Reanalyse Dezidierte zytogenetische Risikostratifizierung von neu diagnostizierten Myelompatienten ohne Hyperdiploidie oder IgH-Translokation: Die Rolle primärer und sekundärer Aberrationen neu beleuchtet Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning Impaired SARS-CoV-2-specific CD8+ T cells after infection or vaccination but robust hybrid t cell immunity in patients with multiple myeloma Körperliche Aktivität und die zum Sport motivierenden Umstände bei Patient*innen mit Multiplem Myelom – eine prospektive Querschnittsstudie anhand eines standardisierten Fragebogens Physical activity and exercise motivation of multiple myeloma patients: a prospective cross-sectional study Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT Pomalidomide combinations are a safe and effective option after daratumumab failure Daratumumab : Therapie beim multiplen Myelom und bei systemischer Leichtketten-Amyloidose Das blaue Buch : Chemotherapie-Manual Hämatologie und Onkologie Das Blaue Buch : Chemotherapie-Manual Hämatologie und Onkologie Das rote Buch : Hämatologie und Internistische Onkologie Das Rote Buch : Hämatologie und Internistische Onkologie Eine randomisierte, prospektive Pilotstudie zur Evaluierung körperlicher Aktivität unter Therapie bei transplantierbaren Patienten mit symptomatischem Myelom (REAL-FITNESS) Impact of photon-counting detector computed tomography on image quality and radiation dose in patients with multiple myeloma Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers Pomalidomide combinations are a safe and effective option after daratumumab failure Pomalidomide combinations are a safe and effective option after daratumumab failure Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma Exploring stem cell transplanted patients’ perspectives on medication self-management and electronic monitoring devices measuring medication adherence: a qualitative sub-study of the Swiss SMILe implementation science project Interdisziplinäre Analyse des Multiplen Myeloms – Klinische Warnzeichen und Diagnosezeit Optimierung der Detektion minimaler Resterkrankung (MRD) beim Multiplen Myelom: Etablierung, Evaluierung und Vergleichsanalyse eines hochsensitiven 10-Farben Durchflusszytometrie Panels in primären Knochenmark- und Leukapherisatproben mit differenter Myelomlast P957: Carfilzomib, lenalidomide, dexamethasone followed by a second auto-HCT is an effective strategy in first relapse multiple myeloma: a study of the chronic malignancies working party of EBMT Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics The role of the APC/C and its coactivators Cdh1 and Cdc20 in cancer development and therapy Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth—the SMILe study Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde Allogeneic stem cell transplantation in multiple myeloma Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network Choosing the right therapy for patients with relapsed/refractory multiple myeloma (RRMM) in consideration of patient-, disease- and treatment-related factors Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort Compliance with vaccination recommendations among patients with multiple myeloma: a real world experience Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth - the SMILe study Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma Funktionelles Assessment bei Patienten mit Multiplem Myelom: ein Ansatz zur Abschätzung der Prognose, Überwachung der Behandlung und Individualisierung von Therapieentscheidungen Geriatric assessments and frailty scores in multiple myeloma patients : : a needed tool for individualized treatment?

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Monika Engelhardt (1966-)

Reduced intensity conditioning prior autologous stem cell transplantation in elderly DLBCL patients

The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities

Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany

Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era

Das interdisziplinäre Tumorboard „Multiples Myelom“ des Comprehensive Cancer Center Freiburg: eine Reanalyse

Dezidierte zytogenetische Risikostratifizierung von neu diagnostizierten Myelompatienten ohne Hyperdiploidie oder IgH-Translokation: Die Rolle primärer und sekundärer Aberrationen neu beleuchtet

Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines

Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning

Impaired SARS-CoV-2-specific CD8+ T cells after infection or vaccination but robust hybrid t cell immunity in patients with multiple myeloma

Körperliche Aktivität und die zum Sport motivierenden Umstände bei Patient*innen mit Multiplem Myelom – eine prospektive Querschnittsstudie anhand eines standardisierten Fragebogens

Physical activity and exercise motivation of multiple myeloma patients: a prospective cross-sectional study

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities

Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany

Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial

Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era

Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

Pomalidomide combinations are a safe and effective option after daratumumab failure

Daratumumab : Therapie beim multiplen Myelom und bei systemischer Leichtketten-Amyloidose

Das blaue Buch : Chemotherapie-Manual Hämatologie und Onkologie

Das Blaue Buch : Chemotherapie-Manual Hämatologie und Onkologie

Das rote Buch : Hämatologie und Internistische Onkologie

Das Rote Buch : Hämatologie und Internistische Onkologie

Eine randomisierte, prospektive Pilotstudie zur Evaluierung körperlicher Aktivität unter Therapie bei transplantierbaren Patienten mit symptomatischem Myelom (REAL-FITNESS)

Impact of photon-counting detector computed tomography on image quality and radiation dose in patients with multiple myeloma

Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab

Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers

Pomalidomide combinations are a safe and effective option after daratumumab failure

Pomalidomide combinations are a safe and effective option after daratumumab failure

Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis

Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians

The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review

Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers

Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence

Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma

Exploring stem cell transplanted patients’ perspectives on medication self-management and electronic monitoring devices measuring medication adherence: a qualitative sub-study of the Swiss SMILe implementation science project

Interdisziplinäre Analyse des Multiplen Myeloms – Klinische Warnzeichen und Diagnosezeit

Optimierung der Detektion minimaler Resterkrankung (MRD) beim Multiplen Myelom: Etablierung, Evaluierung und Vergleichsanalyse eines hochsensitiven 10-Farben Durchflusszytometrie Panels in primären Knochenmark- und Leukapherisatproben mit differenter Myelomlast

P957: Carfilzomib, lenalidomide, dexamethasone followed by a second auto-HCT is an effective strategy in first relapse multiple myeloma: a study of the chronic malignancies working party of EBMT

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics

The role of the APC/C and its coactivators Cdh1 and Cdc20 in cancer development and therapy

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth—the SMILe study

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab

Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde

Allogeneic stem cell transplantation in multiple myeloma

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network

Choosing the right therapy for patients with relapsed/refractory multiple myeloma (RRMM) in consideration of patient-, disease- and treatment-related factors

Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort

Compliance with vaccination recommendations among patients with multiple myeloma: a real world experience

Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia

Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth - the SMILe study

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma

Funktionelles Assessment bei Patienten mit Multiplem Myelom: ein Ansatz zur Abschätzung der Prognose, Überwachung der Behandlung und Individualisierung von Therapieentscheidungen

Geriatric assessments and frailty scores in multiple myeloma patients : : a needed tool for individualized treatment?